Drug data last refreshed Yesterday
WELLBUTRIN SR is an extended-release oral tablet formulation of bupropion hydrochloride, approved in 1996 for major depressive disorder and seasonal affective disorder. It works through presumed noradrenergic and dopaminergic mechanisms, weakly inhibiting neuronal reuptake of norepinephrine and dopamine without affecting serotonin or monoamine oxidase. This unique mechanism differentiates it from SSRIs and other conventional antidepressants.
Declining revenue and approaching loss of exclusivity signal mature-stage brand management with focus on cost containment and generic transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
Worked on WELLBUTRIN SR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moGSK is hiring 10 roles related to this product
WELLBUTRIN SR currently shows no active job openings linked to the product, reflecting its late-stage lifecycle position. Working on this product typically involves defending market share against generics and managing stakeholder expectations during transition to LOE.